Oryzon Genomics (ORY) Q3 2025 earnings summary

Executive summary

• Net result improved by $1.1M year-over-year as of September 30, 2025, aided by the termination of a convertible bonds facility.

• Over $60M secured in the first half of 2025, supporting a strategic focus on CNS clinical programs.

• Strengthened clinical, strategic, and regulatory teams with experienced professionals and new advisory board members.

Financial highlights

• R&D expenses rose to $3.9M for Q3 and $9.6M for the nine months ended September 30, 2025, up from $1.9M and $7.1M year-over-year.

• General and administrative expenses increased to $1.2M for Q3 and $3.9M for the nine months, compared to $0.9M and $3.1M in 2024.

• Net loss for Q3 was $1.2M and $4.6M for the nine months, versus $1.1M and $3.8M in 2024.

• Cash, cash equivalents, and marketable securities totaled $40.4M as of September 30, 2025.

• Total assets reached $171M, and stockholders' equity was $137M as of September 30, 2025.

Outlook and guidance

• Plans to revise and resubmit the Phase III PORTICO-2 protocol for BPD following FDA feedback.

• Strategic focus on CNS, with ongoing and planned trials in BPD, schizophrenia, and ASD.

• Exploring partnerships for oncology-hematology asset iadademstat to strengthen the balance sheet.